Who is sponsoring NCT00719303?

NCT00719303 is sponsored by Gynecologic Oncology Group.

What drugs are being tested in NCT00719303?

Interventions in NCT00719303: Behavioral Dietary Intervention, Compliance Monitoring, Counseling, Educational Intervention, Exercise Intervention, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration.

What condition does NCT00719303 study?

NCT00719303 studies Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Malignant Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIA Ovarian Cancer AJCC V6 and v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Ovarian Cancer AJCC v6 and v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Ovarian Cancer AJCC v6 and v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7, Undifferentiated Fallopian Tube Carcinoma, Undifferentiated Ovarian Carcinoma.

Is NCT00719303 still recruiting?

NCT00719303 is currently status unknown. Last updated 19 February 2018.

Last reviewed 2018-02-19 · How we verify

NCT00719303

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Status unknown Phase 3 Last updated 19 February 2018

What this trial tests

Phase 3 trial testing Behavioral Dietary Intervention in Fallopian Tube Clear Cell Adenocarcinoma in 1,070 participants. Status unknown.

Timeline

18 June 2012

Primary endpoint
31 December 2020

Quick facts

Lead sponsor	Gynecologic Oncology Group
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	1,070
Start date	18 June 2012
Primary completion	31 December 2020
Sites	687 locations across United States

Drugs / interventions tested

Behavioral Dietary Intervention
Compliance Monitoring
Counseling
Educational Intervention
Exercise Intervention
Laboratory Biomarker Analysis — full drug profile →
Quality-of-Life Assessment
Questionnaire Administration

Conditions studied

Fallopian Tube Clear Cell Adenocarcinoma — all drugs for Fallopian Tube Clear Cell Adenocarcinoma →
Fallopian Tube Endometrioid Adenocarcinoma — all drugs for Fallopian Tube Endometrioid Adenocarcinoma →
Fallopian Tube Mucinous Adenocarcinoma — all drugs for Fallopian Tube Mucinous Adenocarcinoma →
Fallopian Tube Serous Adenocarcinoma — all drugs for Fallopian Tube Serous Adenocarcinoma →

Sponsor

Gynecologic Oncology Group — full company profile →

Who can join

18 and older, female only, with Fallopian Tube Clear Cell Adenocarcinoma or Fallopian Tube Endometrioid Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized phase III trial studies whether changes in diet and physical activity can increase the length of survival without the return of cancer (progression-free survival) compared with usual care in patients with previously treated stage II, III, or IV ovarian, fallopian tube, or primary peritoneal cancer. A healthy diet and physical activity program and counseling may help patients make healthier lifestyle choices. It is not yet known whether changes in diet and exercise may help increase progression-free survival in patients with previously treated cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management.
Pati S, Irfan W, Jameel A, Ahmed S, et al · · 2023 · cited 393× · PMID 36672434 · DOI 10.3390/cancers15020485
Physical Activity Reduces the Risk of Recurrence and Mortality in Cancer Patients.
Brown JC, Gilmore LA. · · 2020 · cited 48× · PMID 31913187 · DOI 10.1249/jes.0000000000000214
A randomized trial of diet and physical activity in women treated for stage II-IV ovarian cancer: Rationale and design of the Lifestyle Intervention for Ovarian Cancer Enhanced Survival (LIVES): An NRG Oncology/Gynecologic Oncology Group (GOG-225) Study.
Thomson CA, Crane TE, Miller A, Garcia DO, et al · · 2016 · cited 42× · PMID 27394382 · DOI 10.1016/j.cct.2016.07.005
Targeting obesity-related dysfunction in hormonally driven cancers.
Rubinstein MM, Brown KA, Iyengar NM. · · 2021 · cited 39× · PMID 33911195 · DOI 10.1038/s41416-021-01393-y
Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): Recruitment, retention and baseline characteristics of a randomized trial of diet and physical activity in ovarian cancer survivors.
Thomson CA, Crane TE, Miller A, Gold MA, et al · · 2023 · cited 17× · PMID 36608382 · DOI 10.1016/j.ygyno.2022.12.017
Adipocyte Microenvironment in Ovarian Cancer: A Critical Contributor?
Duarte Mendes A, Freitas AR, Vicente R, Vitorino M, et al · · 2023 · cited 11× · PMID 38068912 · DOI 10.3390/ijms242316589
Translating energy balance research from the bench to the clinic to the community: Parallel animal-human studies in cancer.
Garcia MB, Schadler KL, Chandra J, Clinton SK, et al · · 2023 · cited 11× · PMID 36825928 · DOI 10.3322/caac.21773
Development and Evaluation of an Accelerometer-Based Protocol for Measuring Physical Activity Levels in Cancer Survivors: Development and Usability Study.
Crane TE, Skiba MB, Miller A, Garcia DO, et al · · 2020 · cited 10× · PMID 32969828 · DOI 10.2196/18491

Verify or expand the search:

Other trials of Behavioral Dietary Intervention

Trials testing the same drug.

NCT06733363 — A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscl · Phase 2 · recruiting
NCT06643455 — Mindfulness Intervention for Improving Nutrition in the Digital Kitchen Among Stage I-III Breast Cancer Survivors, MIND · NA · active not recruiting
NCT06315296 — An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing Neurocognitive Decline and Improving Surviva · NA · terminated
NCT06030427 — Virtual Mindfulness and Weight Management to Mitigate Risk of Relapse and Improve Wellbeing in Cancer Survivors · NA · completed
NCT04548193 — Behavioral Dietary Intervention for the Improvement of Bladder Cancer Survivorship · Phase 1 · completed

Other recruiting trials for Fallopian Tube Clear Cell Adenocarcinoma

Currently open trials in the same condition.

NCT06639074 — Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fa · Phase 2 · recruiting
NCT04919629 — APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurr · Phase 2 · recruiting
NCT04575935 — Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal · Phase 3 · recruiting
NCT04092270 — A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansi · Phase 1 · active not recruiting
NCT02502266 — Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Pl · Phase 2, PHASE3 · active not recruiting

Other Gynecologic Oncology Group trials

Trials by the same sponsor.

NCT04393285 — Abemaciclib and Letrozole to Treat Endometrial Cancer · Phase 2 · active not recruiting
NCT03673124 — Ribociclib and Letrozole Treatment in Ovarian Cancer · Phase 2 · active not recruiting
NCT02065687 — Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent · Phase 2, PHASE3 · unknown
NCT01720173 — Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer · Phase 2 · completed
NCT01406769 — Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stag · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00719303 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gynecologic Oncology Group
Last refreshed: 19 February 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00719303.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing